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Cell growth: Downstream of Myc — to grow or to cycle?
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For many years, Myc function has been linked to the
control of cell-cycle progression. Now, increasing
evidence shows that Myc also controls cell growth, and
that these two processes are regulated independently.
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A balance of cell growth, cell proliferation, apoptosis and
terminal differentiation is important in ensuring the
normal development of an organism. Defects in these
processes can lead to developmental abnormalities and, in
some cases, cancer progression. The genes involved in
regulating these various processes therefore need to be
tightly controlled. The c-myc proto-oncogene, which is
often rearranged and deregulated in a wide range of
tumors, encodes a key regulator of cell proliferation and
apoptosis. Recent studies have now demonstrated that
Myc has a role in regulating cell growth and that this is
independent of its effects on the cell cycle [1–4].
Early studies of Myc function in the cell cycle showed
that ectopic expression of Myc in culture can be sufficient
to induce quiescent cells, which are in the G0 phase of
the cell cycle, to progress to the G1 phase [5]. In other
systems, Myc needs to cooperate with activated forms of
the Ras oncoprotein to induce cell-cycle entry [6]. On the
basis of these findings, Myc has been viewed as a cell-
cycle regulator, analogous to cyclins or members of the
E2F-family of transcription factors. Indeed, activation of
conditional alleles of Myc leads to a rapid activation of
the kinase activity of cyclin-dependent kinase 2 (Cdk2)
in the Cdk2–cyclin E complex and of E2F-dependent
transcription [7]. Myc and Ras cooperate in both of these
processes [6]. In similar experiments, ectopic expression
of Myc has been shown to partially antagonize the effects
of the cell-cycle inhibitors p27Kip1 and p16Ink4a, prompt-
ing the suggestion that Myc induces cell-cycle entry by
suppressing p27Kip1 function [8].
The first indications that the role of Myc was not that
simple came from the study of a rat fibroblast cell line in
which both alleles of c-myc had been ablated [9]. Such
cells were viable and, as expected, showed greatly
reduced rates of cell proliferation. Unexpectedly, the
major defect in these cells was a deficiency in cell growth,
defined by the accumulation of cell mass and a deficiency
in global mRNA and protein synthesis. Indeed, although
these cells showed cell-cycle defects in the G1 phase,
including a significantly delayed phosphorylation of the
retinoblastoma protein (Rb), the phosphorylation of Rb in
control and Myc-deficient cells occurred when the cells
were at the same size. This finding would argue that a
delay in cell growth might be the primary cause for the
delay in cell-cycle progression.
A paper by Schuhmacher et al. [1] published recently in
Current Biology has extended these studies to look at the
effect of Myc induction in resting B cells. This group was
able to identify conditions under which activation of Myc
alone was insufficient to induce cell-cycle entry but could
still stimulate the cells to grow. Additionally, a number of
potential target genes of Myc thought to be involved in
cell growth were activated under these conditions. Finally,
experiments using roscovitine, a Cdk2 inhibitor, showed
that Myc’s effects on growth were independent of Cdk2
activation and, therefore, of the cell cycle [1]. In similar
studies in fibroblasts, using a conditional expression
system, Myc had been shown to induce cell growth, but
the cells also entered the cell cycle, making it impossible
to dissect these two effects [2]. In addition, Iritani and
Eisenman [3] have reported a Myc-dependent increase in
B-cell size in mice that constitutively express Myc
throughout B-cell development and these effects were
observed independent of the cell-cycle phase.
Perhaps the most compelling study comes from Johnston
et al. [4], who analysed the function of the Drosophila Myc
homologue, dMyc, during development. Using the wing
imaginal disc as a model system for studying the effects of
deregulated dMyc expression, clones with eliminated
dMyc expression exhibited a retardation in cellular growth
and a reduced cell size, whereas overproduction of dMyc
increased both growth rate and cell size. Overexpression
of dMyc promoted progression from the G1 to S phase,
which was then compensated by a prolonged S–G2 phase.
The overall length of the cell cycle was therefore
unchanged and cell doubling times were not altered,
resulting in no increase in total cell number. 
These findings should be compared with previous studies
from the Edgar and Lehner laboratories [10,11] in which
cell-cycle progression had been manipulated in the
Drosophila wing or imaginal disc by either enhancing or
lowering the level of activity of the Drosophila homologues
of E2F, Rb or Cdc2 [10,11]. In every case, the clone size
was maintained, because any alteration in cell number
was balanced by a compensatory alteration in cell size.
Clearly, in Drosophila, Myc has an important effect on cell
growth and does not act purely as a regulator of the cell cycle.
So where do these findings leave us? Johnston et al. [4]
argue from their findings that Myc acts predominantly as a
regulator of cell growth, and indeed many putative target
genes of Myc are involved in cell metabolism [12]. Could
it be that the effects of Myc on cell-cycle progression are
all indirectly mediated by its effects on cell growth? Two
findings argue that this is not the case: First, in exponen-
tially growing rat fibroblasts, conditional activation of Myc
does not alter the kinetics of cell growth or cell prolifera-
tion [7]. Nevertheless, activation of Myc leads to a prema-
ture activation of Cdk2–cyclin E and of E2F-dependent
transcription in cells early after exit from mitosis. At this
time, cells have not reached the size usually required to
pass the restriction point and activate Cdk2–cyclin E
activity. This demonstrates that these cell-cycle effects
are independent of any effect of Myc on cell growth.
Second, at least three genes directly involved in cell-cycle
progression have now been suggested to be direct target
genes of Myc: these encode the cell-cycle phosphatase
Cdc25a [13], E2F2 [14], and cyclin D2 [15]. For example,
induction of cyclin D2 occurs via direct binding of
Myc–Max complexes in the cyclin D2 promoter upstream
of the start site of transcription, and cyclin D2 protein
accumulates rapidly upon induction of Myc [15]. Impor-
tantly, Myc activates transcription of the cyclin D2 gene
even in the presence of cycloheximide, thereby preclud-
ing any indirect effects mediated via cell growth, which
requires protein synthesis. Judged by these criteria, a
stimulation of cell growth and activation of cell prolifera-
tion by Myc appear to be mediated by distinct sets of
target genes. But detailed mechanisms will only be com-
pletely resolved when Myc function is analysed in various
lines of fibroblasts in which single target genes of Myc are
specifically and individually eliminated. Such studies are
just beginning to emerge [15,16]. 
If Myc indeed stimulates both growth and cell-cycle entry
independently, however, why does it need a cooperating
protein like Ras? And why, for example, does Ras syner-
gize with Myc in Cdk activation? Clearly, models in which
both oncogenes control separate physiological processes
are unlikely, since Ras, like Myc, has been implicated in
the control of both cell growth and cell-cycle progression
via distinct effector pathways [17]. Rather, it appears that
the control of cell proliferation by Myc and Ras is inti-
mately coordinated at multiple levels. For example, in the
REF52 rat fibroblast cell line ectopic expression of Myc is
unable to promote G1 progression and target gene activa-
tion, because Myc protein is rapidly degraded. Expression
of activated Ras stabilises Myc protein and allows activa-
tion of Myc target genes and S-phase entry, suggesting
that Ras acts in a pathway controlling Myc stability [18].
Similarly, recent work shows that Cdk2–cyclin E activity
is inhibited by both p27Kip1 and the Rb-family member
p130 in quiescent cells and both inhibitors dissociate
from Cdk2–cyclin E complexes upon mitogenic stimula-
tion [19]. The processes controlling each inhibitor are
very different, however, and although Myc function has
been linked to p27Kip1 [15], no evidence suggests that
Myc controls p130 function. Potentially, therefore, Myc
and Ras collaborate in Cdk activation by controlling dis-
tinct inhibitor pathways. Finally, recent work indicates
that Myc recruits TRRAP, a component of a histone
acetylation complex, to Myc-binding sites on DNA [20],
and that at least some target genes are controlled by Myc
via changes in histone acetylation. An attractive hypothe-
sis, therefore, is that Myc not only activates target genes
directly, but also alters the chromatin structure of the pro-
moters of such genes to make them accessible for a
second — for example, Ras-dependent — signal. In this
way, Myc would make cells and promoters permissive for
mitogenic signalling by Ras.
The findings also suggest that the ability of Myc to stimu-
late cell proliferation results from co-ordinate changes in
expression of a potentially large number of target genes.
But, irrespective of the mechanism by which Myc acti-
vates its target genes, it is now clear that, besides the role
of Myc in the control of cell-cycle progression, we must
also focus on the control of cell growth as an additional
major function of Myc. 
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